SQSTM1 and CLN6 disease: LC3-II/LC3-I levels are further enhanced, with no effect on p62 levels, with the treatment of the autophagy inhibitor CQ in retinas from CLN6 disease mice (Figure 2) (von Eisenhart-Rothe et al., 2018).